Lucid Capital Markets Starts Insight Molecular Diagnostics Inc. (IMDX) at Buy Aug 24, 2026 06:09AM
Needham: 'we think that the event was positive for IMDX' Aug 18, 2026 08:35AM
Insight Molecular Diagnostics Inc. (IMDX) Tops Q2 EPS by 1c Aug 10, 2026 04:38PM
iMDx posts Q2 loss as FDA review of GraftAssureDx continues Aug 10, 2026 04:07PM
iMDx kidney transplant test featured in Lancet study, gets Medicare nod Jul 23, 2026 08:04AM


May 15, 2026 06:25AM BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX)
Apr 1, 2026 06:07AM BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX)
Mar 27, 2026 05:58AM Needham Reiterates Buy Rating on Insight Molecular Diagnostics Inc. (IMDX)
Mar 26, 2026 04:06PM IMDX submits GraftAssureDx to FDA for transplant rejection testing
Mar 13, 2026 08:00AM IMDX study shows GraftAssure assay outperforms standard rejection tests
Feb 26, 2026 04:41PM Insight Molecular Diagnostics partners with Quest Diagnostics for specimen collection services
Jan 13, 2026 09:05AM IMDX supports call for decentralized transplant monitoring test kits
Jan 5, 2026 12:27PM Needham: 'we believe that IMDX is making good progress towards its GraftAssureDx submissions'
Nov 11, 2025 04:51AM Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham
Oct 13, 2025 04:05PM iMDx hires Steven Tahmooressi as marketing VP ahead of 2026 launch
Oct 6, 2025 07:15AM iMDx reports kidney transplant patient maintained graft without immunosuppression
Sep 8, 2025 07:16AM Insight Molecular Diagnostics launches 5,000-patient registry study
Aug 12, 2025 06:41AM Needham Reiterates Buy Rating on Insight Molecular Diagnostics Inc. (IMDX)
Jun 23, 2025 04:06PM iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing